JPMorgan analyst Tycho Peterson downgraded GenMark Diagnostics to Neutral from Overweight with a price target of $7, down from $11. The analyst says that while 2019 marked an "overall solid year," his recent survey of lab managers points to a deteriorating reimbursement outlook for syndromic panel testing within an increasingly competitive molecular diagnostics market. This brings risk of possible erosion of market share and/or pricing going forward for GenMark, Peterson tells investors in a research note. As such, the analyst sees limited upside in GenMark shares relative to the rest of his coverage universe heading into 2020.